Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

382 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer.
Boscolo Bielo L, Trapani D, Nicolò E, Valenza C, Guidi L, Belli C, Kotteas E, Marra A, Prat A, Fusco N, Criscitiello C, Burstein HJ, Curigliano G. Boscolo Bielo L, et al. Among authors: guidi l. Cancer Treat Rev. 2024 May 16;128:102761. doi: 10.1016/j.ctrv.2024.102761. Online ahead of print. Cancer Treat Rev. 2024. PMID: 38772169 Review.
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer.
Cantini L, Trapani D, Guidi L, Boscolo Bielo L, Scafetta R, Koziej M, Vidal L, Saini KS, Curigliano G. Cantini L, et al. Among authors: guidi l. Cancer Treat Rev. 2024 Feb;123:102669. doi: 10.1016/j.ctrv.2023.102669. Epub 2023 Dec 10. Cancer Treat Rev. 2024. PMID: 38141462 Review.
Targeting HER2 heterogeneity in breast and gastrointestinal cancers.
Valenza C, Guidi L, Battaiotto E, Trapani D, Sartore Bianchi A, Siena S, Curigliano G. Valenza C, et al. Among authors: guidi l. Trends Cancer. 2024 Feb;10(2):113-123. doi: 10.1016/j.trecan.2023.11.001. Epub 2023 Nov 25. Trends Cancer. 2024. PMID: 38008666 Review.
382 results